Original research a real-world study of adverse events of nafamostat mesylate and sodium citrate based on the world health organization-VigiAccess database [PDF]
Frontiers in PharmacologyAimsWhile nafamostat mesylate (NM) and sodium citrate serve as commonly used extracorporeal anticoagulants in clinical practice, the characteristics and potential risks of their adverse events (AEs) need to be systematically evaluated.
Mengting Xu, Ziyi Wang, Binbin Yu
doaj +2 more sources
Assessing safety trends of withdrawn medications: A data-driven pharmacovigilance approach using growth models [PDF]
Exploratory Research in Clinical and Social PharmacyBackground: Adverse drug reactions (ADRs) are critical in evaluating a medicine's safety profile during development and post-marketing surveillance. This study focuses on medications linked to major adverse drug reactions (ADRs) that were later taken off
Samadhan Ghubade, Sharvari Shukla
doaj +2 more sources
Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports. [PDF]
Medicine (Baltimore)Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes mellitus and chronic weight management. With its growing global use, continuous pharmacovigilance is essential to detect emerging patterns of adverse drug reactions (ADRs).
Alorfi NM +9 more
europepmc +2 more sources
Adverse drug reaction profiles of histone deacetylase inhibitors [PDF]
Scientific ReportsThe safety and tolerability of histone deacetylase inhibitors (HDACIs) were always a matter of concern. This study aimed to explore the global observational adverse drug reaction (ADR) profiles of the HDACIs: vorinostat, belinostat, panobinostat ...
Ruqayyah Begum +2 more
doaj +2 more sources
Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. [PDF]
Clin Pharmacol TherBRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Sauer N +3 more
europepmc +2 more sources
A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. [PDF]
Medicine (Baltimore)The efficacy of anlotinib, gefitinib, afatinib, and osimertinib in the treatment of non-small cell lung cancer is well established, but there are gaps in the safety evidence. This study used real-world data from the World Health Organization-VigiAccess database to evaluate the post-marketing adverse drug ...
Fang C +8 more
europepmc +2 more sources
Adverse reactions of second-line tyrosine kinase inhibitors in advanced hepatocellular carcinoma treatment: a descriptive analysis from WHO-VigiAccess. [PDF]
Transl Gastroenterol HepatolGiven the increasing use of targeted therapies in clinical practice, we aimed to determine the clinically actionable safety profiles of second-line tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma (HCC) by analysing adverse drug reactions (ADRs) reported in the WHO-VigiAccess database.Retrospective descriptive analysis of ADR ...
Sui W, Duan Y, Cai Z, Xia Y, Li J, Fu J.
europepmc +3 more sources
A severe case of rhabdomyolysis after Moderna mRNA anti‐COVID‐19 vaccine with a literature review
Clinical Case Reports, Volume 11, Issue 5, May 2023., 2023 The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is essential. As the symptoms of rhabdomyolysis are not specific, the threshold to actively search for this complication should be low. Abstract The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is ...
Maria Sheka +3 more
wiley +1 more source
The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency
European Journal of Neurology, Volume 28, Issue 9, Page 2965-2970, September 2021., 2021 From counts of adverse drug reaction reports from databases, the reporting odds ratio can be calculated and serve as a surrogate for the risk of myasthenia worsening due to drugs commonly used in cardiovascular diseases. An increased risk of beta‐blockers and calcium antagonists is confirmed with this method.
Peter Trillenberg +3 more
wiley +1 more source
European Journal of Neurology, Volume 28, Issue 7, Page 2349-2356, July 2021., 2021 Entries in databases of adverse drug reactions can be used to compare the risk of myasthenia worsening due to drugs. We determined a quantitative surrogate (reporting odds ratio [ROR]) for antiepileptic, antidepressant, neuroleptic, and sedative drugs. Although the ROR was increased for some drugs, their ROR was always smaller than for atorvastatin, a ...
Peter Trillenberg +3 more
wiley +1 more source